Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roxane Laboratories, a US-based subsidiary of Boehringer Ingelheim, has received approval for its abbreviated new drug application for levetiracetam tablets, 250mg, 500mg, 750mg, 1,000mg, and oral solution 100mg/ml.
Subscribe to our email newsletter
Levetiracetam is used to treat epilepsy. The product is available for immediate shipment to wholesalers and pharmacies across the US, said Roxane.
Roxane Laboratories’s levetiracetam tablets and oral solution are AB rated to UCB’s Keppra.